Skip Navigation


BJA Advance Access originally published online on July 23, 2008
British Journal of Anaesthesia 2008 101(4):492-497; doi:10.1093/bja/aen216
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
101/4/492    most recent
aen216v1
Right arrow E-Letters: Submit a response to the article
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Staals, L. M.
Right arrow Articles by Hunter, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Staals, L. M.
Right arrow Articles by Hunter, J. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Board of Management and Trustees of the British Journal of Anaesthesia 2008. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function

L. M. Staals1,*, M. M. J. Snoeck2, J. J. Driessen1, E. A. Flockton3, M. Heeringa4 and J. M. Hunter3

1 Department of Anaesthesiology, Pain and Palliative Medicine, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
2 Department of Anaesthesiology, Canisius-Wilhelmina Ziekenhuis, Nijmegen, The Netherlands
3 University Department of Anaesthesia, Liverpool, UK
4 Global Clinical Development, NV Organon, a part of Schering-Plough Corporation, Oss, The Netherlands

* Corresponding author. E-mail: l.staals{at}anes.umcn.nl

Background: Sugammadex, a modified {gamma}-cyclodextrin, is the first selective relaxant binding agent that specifically encapsulates the steroidal neuromuscular blocking agent, rocuronium. The action of rocuronium is prolonged in patients with renal failure. As sugammadex is primarily cleared renally, this phase III trial investigated the efficacy and safety of sugammadex for reversal of rocuronium-induced neuromuscular block (NMB) in patients with end-stage renal failure.

Methods: Thirty adult patients were studied: 15 renally impaired [creatinine clearance (CLCR) <30 ml min–1] and 15 controls (CLCR>80 ml min–1). Anaesthesia was induced and maintained using i.v. opiates and propofol. Neuromuscular monitoring was performed by acceleromyography and train-of-four (TOF) nerve stimulation. Rocuronium (0.6 mg kg–1) was given, followed by a single i.v. dose of sugammadex (2.0 mg kg–1) at reappearance of the second twitch of the TOF. The primary efficacy variable was time from administration of sugammadex to recovery of the TOF ratio to 0.9. Safety variables included clinical evidence of reoccurrence of NMB.

Results: After sugammadex administration, the mean (SD) time to recovery of the TOF ratio to 0.9 was 2.0 (0.72) min in renal patients and 1.65 (0.63) min in controls (NS). Recurrence of NMB was not observed in any patient. No sugammadex-related serious adverse events were reported.

Conclusions: Sugammadex administered at reappearance of T2 rapidly and effectively reverses NMB induced by rocuronium in renal failure and healthy patients. Sugammadex was well tolerated by all patients. Further safety studies on sugammadex in patients with severe renal impairment are warranted.

Keywords: complications, renal; kidney, failure; neuromuscular block, antagonism; neuromuscular block, rocuronium; safety, drug


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Br J AnaesthHome page
A. Srivastava and J. M. Hunter
Reversal of neuromuscular block
Br. J. Anaesth., July 1, 2009; 103(1): 115 - 129.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.